-
Je něco špatně v tomto záznamu ?
Adult growth hormone deficiency in CEE region: Heterogeneity of the patient pathway
I. Shimon, C. Badiu, A. Bossowski, M. Doknic, I. Dzivite-Krisane, V. Hána, J. Kollerova, E. Natchev, M. Pfeifer, N. Szũcs, J. Hey-Hadavi, R. Gomez,
Jazyk angličtina
Typ dokumentu časopisecké články, práce podpořená grantem, přehledy
- MeSH
- dospělí MeSH
- hypofyzární nanismus diagnóza genetika terapie MeSH
- hypopituitarismus diagnóza genetika terapie MeSH
- kritické cesty * MeSH
- lidé MeSH
- lidský růstový hormon nedostatek MeSH
- směrnice pro lékařskou praxi jako téma normy MeSH
- standardní péče * MeSH
- Check Tag
- dospělí MeSH
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- přehledy MeSH
OBJECTIVES: Adult growth hormone deficiency (AGHD) is a rare disease characterised by abnormal body composition, reduced strength and exercise capacity and impaired psychological wellbeing. An advisory board of leading Central and Eastern European (CEE) endocrinologists was assembled to gain insights into the status of AGHD care in the CEE region. Topics of discussion included the position of adult hypopituitarism/AGHD in health system priorities, availability and affordability of treatments, awareness of AGHD, practice guidelines used in CEE countries and provisions for long-term care of patients. DESIGN: Prior to the meeting, the advisors were asked to summarise, using an itemised survey questionnaire, the usual standards of care for patients with AGHD in their country. At the meeting, the panel of experts discussed the findings and thereby elucidated similarities and differences among CEE countries; these were compared with international guideline-recommended practices for AGHD. RESULTS: All CEE countries involved reported having some type of infrastructure in place for care of patients with GHD transitioning from adolescence to adulthood. Most countries reported having at least one specialist centre for patients with AGHD. The main variations across the region included initial entry into healthcare systems, tests required to confirm AGHD diagnosis and medication reimbursement by health authorities. Most CEE countries relied on international society-led guidelines, while some countries have developed national guidelines. CONCLUSION: The CEE Adult Endocrinology Advisory Board meeting recognised considerable diversity in the care and patient pathways for AGHD across CEE countries. Additional work is needed to optimise care of patients with AGHD in the CEE region.
C Davila University of Medicine and Pharmacy National Institute of Endocrinology Bucharest Romania
Children's University Hospital Riga Stradin's University Riga Latvia
Clinical Center of Endocrinology and Gerontology Medical University Sofia Bulgaria
Department of Internal Medicine 1st Faculty of Medicine Charles University Prague Czech Republic
Department of Internal Medicine University Hospital of Comenius University Bratislava Slovakia
Faculty of Medicine University of Ljubljana Slovenia
Pfizer Innovative Health Brussels Belgium
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc20006218
- 003
- CZ-PrNML
- 005
- 20200525140555.0
- 007
- ta
- 008
- 200511s2019 stk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.ghir.2019.06.001 $2 doi
- 035 __
- $a (PubMed)31234055
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a stk
- 100 1_
- $a Shimon, Ilan $u Rabin Medical Center, Petah Tiqva, Israel. Electronic address: Ilanshi@clalit.org.il.
- 245 10
- $a Adult growth hormone deficiency in CEE region: Heterogeneity of the patient pathway / $c I. Shimon, C. Badiu, A. Bossowski, M. Doknic, I. Dzivite-Krisane, V. Hána, J. Kollerova, E. Natchev, M. Pfeifer, N. Szũcs, J. Hey-Hadavi, R. Gomez,
- 520 9_
- $a OBJECTIVES: Adult growth hormone deficiency (AGHD) is a rare disease characterised by abnormal body composition, reduced strength and exercise capacity and impaired psychological wellbeing. An advisory board of leading Central and Eastern European (CEE) endocrinologists was assembled to gain insights into the status of AGHD care in the CEE region. Topics of discussion included the position of adult hypopituitarism/AGHD in health system priorities, availability and affordability of treatments, awareness of AGHD, practice guidelines used in CEE countries and provisions for long-term care of patients. DESIGN: Prior to the meeting, the advisors were asked to summarise, using an itemised survey questionnaire, the usual standards of care for patients with AGHD in their country. At the meeting, the panel of experts discussed the findings and thereby elucidated similarities and differences among CEE countries; these were compared with international guideline-recommended practices for AGHD. RESULTS: All CEE countries involved reported having some type of infrastructure in place for care of patients with GHD transitioning from adolescence to adulthood. Most countries reported having at least one specialist centre for patients with AGHD. The main variations across the region included initial entry into healthcare systems, tests required to confirm AGHD diagnosis and medication reimbursement by health authorities. Most CEE countries relied on international society-led guidelines, while some countries have developed national guidelines. CONCLUSION: The CEE Adult Endocrinology Advisory Board meeting recognised considerable diversity in the care and patient pathways for AGHD across CEE countries. Additional work is needed to optimise care of patients with AGHD in the CEE region.
- 650 _2
- $a dospělí $7 D000328
- 650 12
- $a kritické cesty $7 D019091
- 650 _2
- $a hypofyzární nanismus $x diagnóza $x genetika $x terapie $7 D004393
- 650 _2
- $a lidský růstový hormon $x nedostatek $7 D019382
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a hypopituitarismus $x diagnóza $x genetika $x terapie $7 D007018
- 650 _2
- $a směrnice pro lékařskou praxi jako téma $x normy $7 D017410
- 650 12
- $a standardní péče $7 D059039
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Badiu, Corin $u "C. Davila" University of Medicine and Pharmacy, National Institute of Endocrinology, Bucharest, Romania.
- 700 1_
- $a Bossowski, Artur $u Department of Pediatrics, Endocrinology, Diabetology with a Cardiology Unit, Medical University of Bialystok, Bialystok, Poland.
- 700 1_
- $a Doknic, Mirjana $u Neuroendocrine Department, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of Serbia, Medical Faculty University of Belgrade, Serbia.
- 700 1_
- $a Dzivite-Krisane, Iveta $u Children's University Hospital, Riga Stradin's University, Riga, Latvia.
- 700 1_
- $a Hána, Václav $u 3(rd) Department of Internal Medicine, 1st Faculty of Medicine, Charles University, Prague, Czech Republic.
- 700 1_
- $a Kollerova, Jana $u 5(th) Department of Internal Medicine, University Hospital of Comenius University Bratislava, Slovakia.
- 700 1_
- $a Natchev, Emil $u Clinical Center of Endocrinology and Gerontology, Medical University, Sofia, Bulgaria.
- 700 1_
- $a Pfeifer, Marija $u Faculty of Medicine, University of Ljubljana, Slovenia.
- 700 1_
- $a Szũcs, Nikolette $u Semmelweis University, Budapest, Hungary.
- 700 1_
- $a Hey-Hadavi, Juliana $u Pfizer, New York City, USA.
- 700 1_
- $a Gomez, Roy $u Pfizer Innovative Health, Brussels, Belgium.
- 773 0_
- $w MED00005163 $t Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society $x 1532-2238 $g Roč. 46-47, č. - (2019), s. 44-49
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/31234055 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20200511 $b ABA008
- 991 __
- $a 20200525140555 $b ABA008
- 999 __
- $a ok $b bmc $g 1525076 $s 1096274
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2019 $b 46-47 $c - $d 44-49 $e 20190607 $i 1532-2238 $m Growth hormone & IGF research $n Growth Horm IGF Res $x MED00005163
- LZP __
- $a Pubmed-20200511